Zhi Tong Cai Jing·2025-08-18 06:34Core Viewpoint - Rongchang Biologics (09995) has seen a stock price increase of over 5%, currently trading at 80.6 HKD with a transaction volume of 536 million HKD, following positive news regarding its innovative drug, Taitasip, for treating primary Sjögren's syndrome (pSS) [1] Group 1: Clinical Research Developments - On August 13, Rongchang Biologics announced that its self-developed drug Taitasip, a world-first BLyS/APRIL dual-target fusion protein, has met the primary endpoint of its Phase III clinical trial for pSS [1] - The company plans to submit a marketing application to the National Medical Products Administration (NMPA) as soon as possible, with detailed data to be presented at a major international academic conference [1] Group 2: Market Potential and Future Prospects - CICC released a research report indicating that the positive Phase III clinical results for Taitasip are expected to enhance its future value [1] - Additionally, the company's RC148 has received FDA approval to conduct a Phase II clinical study in the U.S. for various advanced malignant solid tumors, marking its entry into global clinical research [1] - CICC believes that RC148 has international clinical value and potential for overseas expansion [1]